PharmAust Ltd ECQ
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- A$0.14
- Day Range
- A$0.11–0.11
- 52-Week Range
- A$0.04–0.25
- Bid/Ask
- A$0.00 / A$0.00
- Market Cap
- A$43.15 Mil
- Volume/Avg
- 0 / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 76.67
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
PharmAust Ltd operates as a drug discovery and development company in Australia, Switzerland, and internationally. It develops drug discovery intellectual property for the treatment of various cancers in humans and animals. The company offers Monepantel and Albendazole, which are in Phase II clinical trials for the treatment of cancer. It also provides medicinal and synthetic chemistry services on a contract basis to the drug discovery and pharmaceutical industries.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 52
- Website
- https://www.pharmaust.com
Valuation
|
Metric
|
ECQ
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 8.86 |
Price/Sales | 76.67 |
Price/Cash Flow | — |
Price/Earnings
ECQ
Financial Strength
|
Metric
|
ECQ
|
|---|---|
Quick Ratio | 4.44 |
Current Ratio | 4.55 |
Interest Coverage | — |
Quick Ratio
ECQ
Profitability
|
Metric
|
ECQ
|
|---|---|
Return on Assets (Normalized) | — |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
ECQ
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Hxbpzzy | Xtkjtnb | $124.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Mjkqmgdc | Dhbmtl | $114.2 Bil | |||
| Moderna Inc
MRNA
| Xjncpwl | Jss | $53.7 Bil | |||
| argenx SE ADR
ARGX
| Jdfdhqk | Gqzv | $23.0 Bil | |||
| BioNTech SE ADR
BNTX
| Vplxsxmg | Dwcz | $22.2 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Cgyzpqt | Mznxrss | $20.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Pdyvjwl | Pzhghnk | $15.9 Bil | |||
| United Therapeutics Corp
UTHR
| Cwdsrqvy | Jsqg | $12.8 Bil | |||
| Incyte Corp
INCY
| Rpzfykrs | Vshwfv | $12.2 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Lhbhjgysb | Cvsqjhm | $12.2 Bil |